Every 8-K that VASO CORPORATION (VASO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VASO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VASO filings page.
Vaso Corporation completed the sale of all issued and outstanding membership interests of its subsidiary NetWolves Network Services LLC to COEO Solutions, LLC under an Equity Purchase Agreement dated July 31, 2026, for a base purchase price of $14,500 in cash, subject to customary adjustments. An amendment provides unaudited pro forma condensed consolidated financial information reflecting this disposition.
A reconciliation shows net proceeds of $12,806, including closing cash of 400, closing indebtedness of (1,123) and unpaid seller expenses of (971). After a $2,850 escrow receivable, net cash proceeds are $9,956, increasing cash and cash equivalents from 21,973 to 31,929 and adding restricted cash of 2,850. Total assets decline from 82,983 to 79,459, goodwill falls from 10,978 to 1,242, total liabilities drop from 54,381 to 50,033, and stockholders’ equity rises by 824 to 29,426, reflecting an estimated gain.
For the three months ended March 31, 2026, pro forma total revenues decrease from 19,356 to 9,795 after removing managed IT systems and services, while the net loss narrows from 887 to 725. For 2025, pro forma revenues fall from 89,096 to 49,807, but net income increases from 1,569 to 6,162, as NetWolves’ operations and related costs are removed and the estimated gain is included.
Vaso Corporation entered into an Equity Purchase Agreement with COEO Solutions, LLC on July 31, 2026, under which COEO purchased from Vaso and its wholly owned subsidiary VasoTechnology, Inc. all of the issued and outstanding membership interests of NetWolves Network Services LLC. NetWolves provides managed network and multi-technology solutions, including network design, redundancy, application device management, and real-time monitoring, reporting and support.
The base purchase price is $14,500,000.00 in cash, subject to customary post-closing adjustments for net working capital, closing cash, closing indebtedness and unpaid seller expenses. As a result of the transaction, NetWolves ceased to be an indirect wholly owned subsidiary of Vaso. Vaso will file unaudited pro forma condensed consolidated financial information giving effect to the disposition of NetWolves in an amendment, to be included as Exhibit 99.1 within four business days of the closing.
Vaso Corporation appointed Shaun McMeans, age 64, as a Class III director and member of the board’s audit committee, effective July 23, 2026. He is designated as a financial expert based on extensive finance and accounting leadership roles in life sciences and technology companies, including prior service as Chief Financial Officer of HTG Molecular Diagnostics, Inc. and his current role as CFO of Nabsys.
The company states there are no family relationships or related-party transactions involving McMeans and no arrangements with other parties leading to his appointment. As a non-employee director, he will receive pro-rated director compensation and a one-time new director grant of 100,000 shares of Vaso common stock.
Vaso Corporation approved a new incentive arrangement for Peter Castle, President of its wholly-owned subsidiary VasoTechnology Inc. The agreement ties a potential $175,000 incentive payment to Mr. Castle’s role in helping Vaso achieve specified corporate outcomes related to potential strategic initiatives within a defined time period.
If the objectives laid out in the agreement are not achieved in time, or if Mr. Castle does not remain in compliance with the agreement’s terms, he will not receive any portion of the incentive amount.
Vaso Corporation reported that its board amended and restated the company’s bylaws, effective February 11, 2026. The changes give the board more flexibility in scheduling annual stockholder meetings, define what business can occur at special meetings, and add detailed provisions for virtual stockholder meetings and how meetings are chaired and conducted.
The amendments align quorum and board-size language with Vaso’s Articles of Incorporation and remove stockholders’ ability to act without a meeting. They also add a Chief Operating Officer role, separate the duties of the President and Chief Executive Officer, clarify and expand indemnification and expense advancement for officers, allow discretionary indemnification of non-officers, and expressly permit uncertificated shares.
Vaso Corporation reported the results of its annual shareholder meeting held on December 17, 2025. Shareholders elected three Class II directors — Behnam Movaseghi, Jane Moen, and Leon Dembo — to new three‑year terms. As of the record date, 175,953,035 common shares were entitled to vote, and 120,208,576 shares were represented in person or by proxy.
Shareholders approved the non-binding advisory proposal on executive compensation, with 105,612,284 votes for, 12,759,718 against, and 1,836,574 abstentions. In a separate advisory vote on how often to hold future Say on Pay votes, 97,734,812 votes favored a three‑year frequency. Holders of approximately 56% of outstanding shares supported this three‑year schedule, which the Board adopted, so the next Say on Pay vote will occur at the 2028 annual meeting.
Vaso Corporation reported that on November 19, 2025 it entered into an agreement to sell its wholly owned subsidiary, VasoHealthcare IT Corp. The announcement was made the same day through a press release, which is included as an exhibit to this report. This move means Vaso plans to exit direct ownership of its healthcare IT subsidiary, though specific terms such as price, buyer, and closing conditions are not described in this excerpt.